Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
University of Chicago Medical Center, Chicago, Illinois UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania